PDF herunterladen
TumorDiagnostik & Therapie 2006; 27(1): 37-43
DOI: 10.1055/s-2006-926595
Thieme Onkologie aktuell

© Georg Thieme Verlag Stuttgart · New York

Geriatrische Urologie - Tumorerkrankungen

Geriatric Urology - Tumour DiseasesS. Krege1 , C. Friedrich1 , L. Pientka1 , H. Rübben1
  • 1Urologische Universitätsklinik Essen
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. Februar 2006 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Durch die Entwicklung der Bevölkerungsstruktur werden die urologischen Tumore als typische Tumore des höheren Lebensalters an Bedeutung zunehmen. Die hauptsächlich betroffene Patientengruppe weist häufig relevante Komorbiditäten und funktionelle Beeinträchtigungen auf, die in der Therapieplanung berücksichtigt werden müssen. In den letzten Jahrzehnten konnten im Bereich der operativen Versorgung urologischer Tumore erhebliche Fortschritte in den perioperativen Komplikationsraten erzielt werden. Dabei kommt vor allem einem interdisziplinärem perioperativem Management eine große Bedeutung zu, da die Prognose-relevanten Komplikationen vor allem nicht-urologische Probleme wie Infektionen, Verwirrtheitszustände, etc. betreffen. Gleichzeitig konnten in der systemischen Therapie des Prostatakarzinoms mit der Einführung der Taxane erstmalig Überlebensvorteile für eine palliative Chemotherapie erzielt werden. Mit Einführung des Gemcitabins in die Therapie der Blasentumore scheinen den bisherigen MVAC-Protokoll äquipotente, aber besser verträgliche Therapieprotokolle möglich. Die Rolle der Wachstumsfaktoren muss in der Therapie der urologischen Tumore noch definiert werden, sei es in der Intensivierung bisheriger Therapieschemata oder in der Verbesserung der Verträglichkeit der Protokolle. Eine interdisziplinäre Zusammenarbeit zwischen Urologen, Internisten und Geriatern ist zur adäquaten Individualisierung des Therapievorgehens sinnvoll und sollte proaktiv erfolgen.

Abstract

Due to demographic developments malignancies of urogenital origin will gain increasing importance. The urologist will face a growing group of patients with co-morbidities and functional disabilities as these neoplasms increase with age. Optimisation of peri-interventional management successfully reduces the risks of surgery. Integration of taxane-based cytostatic regimes achieves a prolongation of survival in hormone-refractory metastatic prostatic cancer. The introduction of gemcitabine in the management of malignancies of the bladder seems to have reduced toxicity while maintaining anti-tumour activity in comparison to MVAC. The role of haematopoetic growth factors remains to be defined in urologic malignancies - increasing dose intensity for better activity or reduction of toxicity. Individualisation of treatment requires early cooperation of the urologist, the oncologist and the geriatrician for an optimal outcome.

Schlüsselwörter

geriatrische Onkologie - Komorbidität - peripoperatives Management - systemische Chemotherapie

Key words

Geriatric oncology - co-morbidities - perioperative management - systemic chemotherapy

Literatur

  • 1 Katz S, Branch L G, Branson M H, Papsidero J A, Beck J C, Greer D S. Active life expectancy.  N Engl J Med. 1983;  27 1218-1224
    PubMedGoogle Scholar
  • 2 Yancik R, Havlik R J. et al . Cancer and comorbidity in older patients: a descriptive profile.  Ann Epidemiol. 1996;  27 399-412
    PubMedGoogle Scholar
  • 3 Coebergh J W, Janssen-Heijnen M L. et al . Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993 - 1996.  J Clin Epidemiol. 1999;  27 1131-1136
    PubMedGoogle Scholar
  • 4 Albertsen P C, Fryback D G. et al . The impact of co-morbidity on life expectancy among men with localized prostate cancer.  J Urol. 1996;  27 127-132
    PubMedGoogle Scholar
  • 5 Welch H G, Albertsen P C. et al . Assessing competing risks in treating the elderly.  Hosp Pract (Off Ed). 1996;  27 155-156, 158 - 159, 162, passim
    PubMedGoogle Scholar
  • 6 Newschaffer C J, Bush T L. et al . Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients.  J Gerontol Biol Sci Med Sci. 1996;  27 372-378
    PubMedGoogle Scholar
  • 7 Kattan M W, Cowen M E. et al . A decision analysis for treatment of clinically localized prostate cancer.  J Gen Intern Med. 1997;  27 299-305
    PubMedGoogle Scholar
  • 8 Barry M J, Albertsen P C, Bagshaw M A. et al . Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis.  Cancer. 2001;  27 2302-2314
    PubMedGoogle Scholar
  • 9 Froehner M, Koch F R, Litz R. et al . Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy.  Urology. 2003;  27 698-701
    PubMedGoogle Scholar
  • 10 Froehner M, Koch R, Litz R. et al . Which conditions contributing to the Charlson score predict survival after radical prostatectomy?.  J Urol. 2004;  27 97-699
    PubMedGoogle Scholar
  • 11 Extermann M. Measuring comorbidity in older cancer patients.  Eur J Cancer. 2000;  27 453-471
    PubMedGoogle Scholar
  • 12 Wolters U, Wolf T, Stutzer H. ASA classifications and perioperative variables as predictors of postoperative outcome.  Br J Anesth. 1996;  27 217-222
    PubMedGoogle Scholar
  • 13 Charlson M E, Pompei P, Ales K L. et al . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;  27 373-383
    PubMedGoogle Scholar
  • 14 Greenfield S, Blanco D M. et al . Patterns of care related to age of breast cancer patients.  J Am Med Assoc. 1987;  27 2766-2770
    PubMedGoogle Scholar
  • 15 Kaplan M H, Feinstein A R. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.  J Chronic Dis. 1974;  27 387-404
    CrossrefPubMedGoogle Scholar
  • 16 Cohen H J. Cancer and the functional status of the elderly.  Cancer. 1997;  27 1883-1886
    PubMedGoogle Scholar
  • 17 Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly.  Eur J Cancer. 1999;  27 1771-1772
    PubMedGoogle Scholar
  • 18 Serraino D, Fratino L, Zagonel V. Prevalence of functional disability among elderly patients with cancer.  Crit Rev Oncol Hematol. 2001;  27 269-273
    PubMedGoogle Scholar
  • 19 Krege S, Friedrich C. et al . Geriatrisches Assessment: Sinnvolle Hilfe bei der Auswahl älterer Tumorpatienten für eine belastende Therapie?.  Urol A. 2004;  27 922-929
    PubMedGoogle Scholar
  • 20 Friedrich C, Pientka L, Kolb G. et al . Comprehensive geriatric assessment in the elderly cancer patient.  Onkologie. 2003;  27 355-360
    PubMedGoogle Scholar
  • 21 Thomas D M, Riddle P R. Morbidity and mortality in 100 consecutive radical cystectomies.  Br J Urol. 1982;  27 716-719
    PubMedGoogle Scholar
  • 22 Rosario D J, Becker M, Anderson J B. The changing pattern of mortality and morbidity from radical cystectomy.  Br J Urol. 2000;  27 427-430
    PubMedGoogle Scholar
  • 23 Peyromaure M, Guerin F, Debre B, Zerbib M. Surgical management of infiltrating bladder cancer in elderly patients.  Eur Urol. 2004;  27 147-154
    PubMedGoogle Scholar
  • 24 Figueroa A, Stein J P, Dickinson M. et al . Radical cystectomy for elderly patients with bladder carcinoma.  Cancer. 1998;  27 141-147
    PubMedGoogle Scholar
  • 25 Chang S S, Alberts G, Cookson M S, Smith J A. Radical cystectomy is safe in elderly patients at high risk.  J Urol. 2001;  27 938-941
    PubMedGoogle Scholar
  • 26 Lance R S, Dinney C P, Swanson D. et al . Radical cystectomy for invasive cancer in the octogenarian.  Oncol Rep. 2001;  27 723-726
    PubMedGoogle Scholar
  • 27 Stroumbakis N, Herr H W, Cookson M S, Fair W R. Radical cystectomy in the octogenarian.  J Urol. 1997;  27 2113-2117
    PubMedGoogle Scholar
  • 28 Game' X, Soulie M, Seguin P. et al . Radical cystectomy in patients older than 75 years: Assessment of morbidity and mortality.  Eur Urol. 2001;  27 525-529
    PubMedGoogle Scholar
  • 29 Frazier H A, Robertson J E, Paulson D F. Complication of radical cystectomy and urinary diversion: a retrospective study of 675 cases in 2 decades.  J Urol. 1992;  27 1401-1404
    PubMedGoogle Scholar
  • 30 Hautmann R E, Petriconi R de, Gottfried H W. et al . The ileal neobladder: complications and functional results in 363 patients after 11 years of followup.  J Urol. 1999;  27 422-427
    PubMedGoogle Scholar
  • 31 Stein J P, Liesskowsky G, Cote R. et al . Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1054 patients.  J Clin Oncol. 2001;  27 666-675
    PubMedGoogle Scholar
  • 32 Leibovitch I, Avigad I, Ben-Chaim J. et al . Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder?.  Cancer. 1993;  27 3098-3101
    PubMedGoogle Scholar
  • 33 Takashi S, Bunzo S, Tadashi M. et al . Orthotopic neobladder reconstruction in elderly bladder cancer patients.  Int J Urol. 2001;  27 533-538
    PubMedGoogle Scholar
  • 34 Gschwend J E, Hautmann R E, Volkmer B G. Radikale Zystektomie und Harnableitung beim älteren Patienten mit erhöhter Komorbidität.  Urol A. 2004;  27 930-934
    PubMedGoogle Scholar
  • 35 Clark P E, Stein J P, Groshen S G. et al . Radical cystectomy in the elderly: comparison of survival between younger and older patients.  Cancer. 2005;  27 546-552
    PubMedGoogle Scholar
  • 36 Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient.  Semin Oncol. 1989;  27 76-84
    PubMedGoogle Scholar
  • 37 Lindemann R D. Overview: renal physiology and pathophysiology of aging.  Am J Kidney Diss. 1990;  27 275-282
    PubMedGoogle Scholar
  • 38 Enright P L. Aging of the Respiratory System. In: Hazzard WR et al. (eds.) Principles of Geriatric Medicine & Gerontology. New York: McGraw-Hill 2003: 511-515
    Google Scholar
  • 39 Wei J Y. Cardiovascular comorbidity in the older cancer patient.  Semin Oncol. 1995;  27 9-10
    PubMedGoogle Scholar
  • 40 Balducci L, Hardy C L, Lyman G H. Hematopoietic growth factors in the older cancer patient.  Curr Opin Hematol. 2001;  27 170-187
    PubMedGoogle Scholar
  • 41 Bokemeyer C, Honecker F, Wedding U. et al . Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.  Onkologie. 2002;  27 32-39
    PubMedGoogle Scholar
  • 42 Lichtman S M, Skirvin J A, Vernulapalli S. Pharmacology of antineoplastic agents in older cancer patients.  Crit Rev Oncol Hematol. 2003;  27 101-114
    PubMedGoogle Scholar
  • 43 Wit R de. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.  Eur J Cancer. 2005;  27 502-507
    PubMedGoogle Scholar
  • 44 Tannock I F, Wit R de, Berry W R. et al . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.  N Engl J Med. 2004;  27 1502-1512
    PubMedGoogle Scholar
  • 45 Petrylak D P, Tangen C M, Hussain M H. et al . Docetaxel and extramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.  N Engl J Med. 2004;  27 1513-1520
    PubMedGoogle Scholar
  • 46 Abratt R P, Brune D, Dimopoulos M A. et al . Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.  Ann Oncol. 2004;  27 1613-1621
    PubMedGoogle Scholar
  • 47 Sternberg C N, Whelan P, Hetherington J. et al . Phase III trial of satraplatin, an Oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.  Oncology. 2005;  27 2-9
    PubMedGoogle Scholar
  • 48 Bhandari M S, Petrylak D P, Hussain M. Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade?.  Eur J Cancer. 2005;  27 941-953
    PubMedGoogle Scholar
  • 49 Smith M R, Nelson J B. Future therapies in hormone-refractory prostate cancer.  Urology. 2005;  27 9-17
    PubMedGoogle Scholar
  • 50 Bamias A, Efstathiou E, Moulopoulos L A. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.  Ann Oncology. 2005;  27 307-313
    PubMedGoogle Scholar
  • 51 Fossa S D, Sternberg C, Scher H I. et al . Survival of patient with advanced urothelial cancer treated with cisplatin-based chemotherapy.  Br J Cancer. 1996;  27 1655-1659
    PubMedGoogle Scholar
  • 52 Bajorin D F, Dodd P M, Mazumdar M. et al . Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.  J Clin Oncol. 1999;  27 3173-3181
    PubMedGoogle Scholar
  • 53 Roychowdhury D F, Hayden A, Liepa A M. Health-related quality of life parameters as independent prognostic factors in advanced or metastatic bladder cancer.  J Clin Oncol. 2003;  27 673-678
    PubMedGoogle Scholar
  • 54 Millikan R, Dinney C, Swanson D. et al . (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomised trial of cystectomy plus adjuvant MVAC versus cystectomy with both preoperative and postoperative MVAC.  J Clin Oncol. 2003;  27 4005-4013
    PubMedGoogle Scholar
  • 55 Nogue-Aliguer M, Carles J, Arrivi A. et al . Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.  Cancer. 2003;  27 2180-2186
    PubMedGoogle Scholar
  • 56 Vaughn D J, Manola J, Dreicer R. et al . Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction: a trial of the Eastern Co-operative Oncology Group.  Cancer. 2002;  27 1022-1027
    PubMedGoogle Scholar
  • 57 Hussain M, Vaishampayan U, Du W. et al . Combination carboplatin, paclitaxel and gemcitabine is an active treatment for advanced urothelial carcinoma.  J Clin Oncol. 2001;  27 2527-2533
    PubMedGoogle Scholar
  • 58 Castagneto B, Zai S, Marenco D. et al . Single agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.  Oncology. 2004;  27 27-32
    PubMedGoogle Scholar
  • 59 Aparicio A M, Elkhouiery A B, Quinn D I. The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy.  Urol Clin N Am. 2005;  27 217-230
    PubMedGoogle Scholar
  • 60 Goffin J R, Rajan R, Souhami L. Tolerance of radiotherapy and chemotherapy in elderly patients with Bladder cancer.  Am J Clin Oncol. 2004;  27 172-177
    PubMedGoogle Scholar
  • 61 Post P, Kil P, Hendrikx A. et al . Comorbidity in patients with prostate cancer and its relevance to treatment choice.  BJU Int. 1999;  27 652-656
    PubMedGoogle Scholar

Dr. med. S. Krege

Urologische Universitätsklinik Essen

Hufelandstr. 55

45147 Essen

eMail: susanne.krege@uni-essen.de

      >